South Oxfordshire, UK, 8th June 2026 - Inify Laboratories, a unique laboratory
service that provides diagnostics within pathology, today announced that it has
entered into an agreement with University Hospitals Plymouth NHS Trust (UHP) to
launch a service evaluation. The evaluation aims to support the consistent
delivery of a 7-day histopathology turnaround time and improve performance
improvement against the 28-day Faster Diagnosis Standard (FDS). The partnership
seeks to ensure patients with suspected prostate cancer receive timely, high
-quality diagnostic results.
Across the country, cancer waiting times (CWT) remain under significant
pressure, with many NHS trusts struggling to meet national targets for timely
diagnosis and treatment due to high demand and constrained resources. Prostate
cancer diagnostics is one area particularly affected by hugely variable
reporting times. NHS targets, including the 28-day FDS, place clear emphasis on
delivering timely results to patients. Delays in laboratory processing of tissue
and pathology reporting can impact the entire clinical pathway, requiring
additional administrative time to track results, rearrange clinics, and manage
patient expectations.
The collaboration between Inify Laboratories and UHP is designed to support more
consistent and predictable histopathology turnaround times, helping the Trust
reliably achieve its 7-day histopathology target, and helping clinicians receive
high-quality diagnostic reports within agreed timeframes. By combining digital
workflows, AI-supported analysis, and streamlined laboratory processes, the
service evaluation seeks to reduce variation, improve efficiency, and ultimately
enhance patient experience.
"Our goal is to provide a reliable, high-quality service," says Rob Archer and
Louise Keers, Laboratory Operations Managers at UHP. "By releasing laboratory
capacity in one area, we can enable staff to focus on other clinical priorities
and support improved turnaround times across additional indications - helping us
meet national cancer targets more sustainably.''
"We're very pleased to support this service evaluation in partnership with
University Hospitals Plymouth NHS Trust and Inify Laboratories," says Sunita
Berry, Managing Director of the Peninsula Cancer Alliance. "Improving diagnostic
timeliness is a key priority across our region, and initiatives that bring
greater consistency and efficiency to the prostate cancer pathway are extremely
welcome. We're excited to see the potential impact this collaboration could have
for both patients and clinical teams."
"This partnership reflects what can be achieved when clinical expertise, digital
innovation and service design come together," says Kate Bucknall, Managing
Director UK at Inify Laboratories. "Inify delivers a dependable, end-to-end
service that brings greater efficiency and sustainability to the prostate cancer
pathway."
The service evaluation reflects a shared commitment between Inify Laboratories
and UHP to improve cancer pathways, reduce patient anxiety associated with
waiting for results, and support sustainable cancer diagnostic services for the
future.
For further information, please contact Kate Bucknall, Managing Director, Inify
Laboratories Ltd, kate.bucknall@inify.com, or visit https://www.inify.com
###
This information is considered to be inside information pursuant to the EU
Market Abuse Regulation (MAR) and is subject to the disclosure requirements
pursuant to MAR article 17 and section 5-12 the Norwegian Securities Trading
Act.
This stock exchange announcement was published by Ann-Charlotte Linderoth, Inify
Laboratories AB on the time and date provided.
###
The future of diagnostics
Inify Laboratories offers diagnostics through specialised laboratory services in
histopathology, with a focus on streamlining patient pathways. The company
performs clinical diagnostics in prostate cancer and gastroenterology, providing
an integrated service that spans from early sample handling to final diagnosis.
The laboratory system is scalable both in handling large volumes of patient
samples and for replicating in new locations.
Quality and response times are optimised in every step - from logistics to
tissue preparation and diagnosis - using a fully digital, standardised and AI
-assisted workflow. The diagnosis is always performed by a pathologist and is
assisted by Inify's proprietary AI, proven to have world-leading precision in
clinical evaluations. The entire workflow is supported by a tailor-made system
that also enables development to include additional diagnostic areas.
Inify Laboratories is an international group headquartered in Solna, Sweden,
with local laboratories in Sweden and the UK. The company's share is listed on
Euronext Growth Oslo (https://live.euronext.com/en/product/equities/SE0017486103
-MERK) under the ticker
INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)
/en/product/equities/SE0017486103\
-MERK) under the ticker\
INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)\